We are live on ! Find out more
OCRX

Ocera Therapeutics, Inc.
OCRX

Delisted

OCRX was delisted on the 8th of December, 2017.

Back to rankings

31 hedge funds and large institutions have $21.3M invested in Ocera Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 6

45% more capital invested

Capital invested by funds: $14.7M → $21.3M (+$6.58M)

6% less funds holding

Funds holding: 33 → 31 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
31
Holders Change
-2
Holders Change %
-6.06%
% of All Funds
0.83%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
2
Increased
10
Reduced
6
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VMI
VHCP Management II
New York
+$350K
2
PVI
Pura Vida Investments
New York
+$295K
3
VM
VHCP Management
New York
+$150K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$54.4K
5
Renaissance Technologies
Renaissance Technologies
New York
+$41.7K

Top Sellers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
-$199K
2
GTC
Ghost Tree Capital
New York
-$68K
3
SM
Sabby Management
Florida
-$60K
4
TI
Turner Investments
Pennsylvania
-$13.2K
5
WMSA
Weiss Multi-Strategy Advisers
New York
-$7.48K
Name Holding Trade Value Shares
Change 		Change in
Stake
GPP
1
Great Point Partners
Connecticut
$5.18M – – –
VMI
2
VHCP Management II
New York
$2.87M +$350K +140,000 +15%
QF
3
QVT Financial
New York
$2.33M – – –
VM
4
VHCP Management
New York
$2.26M +$150K +60,000 +8%
DM
5
Deerfield Management
New York
$1.51M – – –
Millennium Management
6
Millennium Management
New York
$1.36M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$1.14M +$54.4K +21,789 +5%
SM
8
Sabby Management
Florida
$1.06M -$60K -24,000 -6%
PVI
9
Pura Vida Investments
New York
$657K +$295K +117,962 +90%
Renaissance Technologies
10
Renaissance Technologies
New York
$491K +$41.7K +16,700 +10%
VC
11
Vivo Capital
California
$405K – – –
TI
12
Turner Investments
Pennsylvania
$355K -$13.2K -5,297 -4%
BCM
13
Bridgeway Capital Management
Texas
$347K -$199K -79,800 -38%
WMSA
14
Weiss Multi-Strategy Advisers
New York
$290K -$7.48K -2,995 -3%
ECM
15
Endurant Capital Management
California
$272K – – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
$160K +$225 +90 +0.1%
BFA
17
BlackRock Fund Advisors
California
$142K +$19K +7,614 +16%
Stifel Financial
18
Stifel Financial
Missouri
$88K – – –
Bank of New York Mellon
19
Bank of New York Mellon
New York
$85K -$4.18K -1,672 -5%
California Public Employees Retirement System
20
California Public Employees Retirement System
California
$81K – – –
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
$41K – – –
Northern Trust
22
Northern Trust
Illinois
$34K – – –
GT
23
Glenmede Trust
Pennsylvania
$29K – – –
PAM
24
Panagora Asset Management
Massachusetts
$24K +$22.2K +8,899 New
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
$9K -$122 -49 -1%
1
2

OCRX Hedge Fund Activity: Q3 2016 in Review

31 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Ocera Therapeutics, Inc. (OCRX) for Q3 2016, worth a combined $21.3M — up 45% from $14.7M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of OCRX and 2 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 10 added.

The largest buyer was VHCP Management II, adding an estimated $350K. The largest seller was Bridgeway Capital Management, cutting an estimated $199K.

  • 31 institutional investors held Ocera Therapeutics, Inc. (OCRX) as of Q3 2016, down from 33 in Q2 2016.
  • Funds reported $21.3M of Ocera Therapeutics, Inc. stock for Q3 2016, up 45% quarter-over-quarter.
  • 2 funds opened new Ocera Therapeutics, Inc. positions in Q3 2016 and 4 closed out, a net change of -2 holders.
  • The largest Ocera Therapeutics, Inc. buyer in Q3 2016 was VHCP Management II, an estimated $350K added.
  • The largest Ocera Therapeutics, Inc. seller in Q3 2016 was Bridgeway Capital Management, an estimated $199K sold.

Based on aggregated 13F filings for Q3 2016.